Episode
2420: Poolbeg Pharma - POLB 001 Trial Activated as CRS Prevention Study Moves Into Patients
- Podcast
- The Vox Markets Podcast
- Published
- Jun 12, 2026
- Duration seconds
- 231
- Processing state
not_requested- Canonical source
- https://audioboom.com/posts/8915828
Actions
POST https://stenobird.com/v1/public/podcasts/the-vox-markets-podcast-3914537/episodes/2420-poolbeg-pharma-polb-001-trial-activated-as-crs-prevention-study-moves-into-patients/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-vox-markets-podcast-3914537/2420-poolbeg-pharma-polb-001-trial-activated-as-crs-prevention-study-moves-into-patients.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Poolbeg Pharma has announced the activation of the first clinical trial site for its POLB 001 TOPICAL study, marking a key operational milestone for its lead programme. The trial will evaluate POLB 001 as a potential preventative treatment for Cytokine Release Syndrome in relapsed/refractory multiple myeloma patients receiving teclistamab, an approved bispecific antibody. With recruitment now underway and interim data expected in summer 2026, the study could provide an important early readout on POLB 001’s role in improving the safety and accessibility of cancer immunotherapies.